Induced psoriasis after rituximab therapy for rheumatoid arthritis: a case report and review of the literature
- 8 November 2012
- journal article
- case report
- Published by Springer Nature in Rheumatology International
- Vol. 33 (11) , 2927-2930
Abstract
Rituximab is a human/murine monoclonal antibody targeting the CD20 antigen on B-lymphocytes surface. Although it has been licensed for treatment of non-Hodgkin’s lymphoma, nowadays it is also a novel therapy for autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus. Despite the increasing evidence regarding the safety and efficacy of rituximab in these conditions, many cutaneous adverse events have been reported. Here, we describe the case of a 69-year-old patient, affected by rheumatoid arthritis, who developed psoriatic lesions on her trunk and arms, three months after the second course of rituximab. Similar cases appearing in the literature will also be briefly mentioned.Keywords
This publication has 15 references indexed in Scilit:
- Incidence of New-onset and Flare of Preexisting Psoriasis During Rituximab Therapy for Rheumatoid Arthritis: Data from the French AIR RegistryThe Journal of Rheumatology, 2012
- Worsening of psoriasis with rituximab therapy.2011
- The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trialsRheumatology International, 2010
- Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab.2010
- Pathogenic Mechanisms Shared between Psoriasis and Cardiovascular DiseaseInternational Journal of Medical Sciences, 2010
- Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphomaAnnals of the Rheumatic Diseases, 2008
- Development of psoriasis after B cell depletion with rituximabArthritis & Rheumatism, 2007
- The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trialArthritis & Rheumatism, 2006
- Rituximab‐induced serum sicknessAmerican Journal of Hematology, 2002
- Rituximab-Induced VasculitisDermatology, 2001